METiS TechBio在香港IPO募資約21.1億港元(約2.7億美元),發行價10.50港元,首日開盤28.68港元,較發行價暴漲約173%,盤中一度上漲約185%。[2][12] 公司利用人工智慧與奈米材料設計藥物遞送系統,被形容為可將治療分子精準送入細胞的「奈米火箭」。[1][10] 香港市場近年出現AI生技IPO熱潮,已有超過10家尚未盈利的生技公司申請上市,顯示投資人對AI藥物研發平台興趣迅速升溫。[20]

Create a landscape editorial hero image for this Studio Global article: What should investors know about METiS TechBio’s Hong Kong IPO debut, including how much its shares surged, how much money the company raise. Article summary: METiS TechBio’s Hong Kong debut was a hot AI-biotech IPO: its shares opened 173.14% above the HK$10.50 offer price at HK$28.68, while some reports said the stock rose as much as 185% intraday. The company raised about HK. Topic tags: general, general web. Reference image context from search candidates: Reference image 1: visual subject "On April 19, Metis TechBio (stylized as “METiS TechBio”) announced that it had cleared its listing hearing at Hong Kong Exchanges and Clearing (HKEX), a key step toward a Hong Kong" source context "Metis TechBio clears key listing hurdle with AI nanodelivery focus" Reference image 2: visual subject "Founded in 2020, Metis uses a
METiS TechBio在香港股市的首次公開募股(IPO)引發市場高度關注,成為2026年最受討論的AI生技上市案之一。公司上市首日股價暴漲超過170%,顯示投資人對「AI+醫藥」題材的高度熱情。[2][
10]
這家成立不久的生技新創,主打用人工智慧設計奈米級藥物遞送系統,目標是解決現代醫藥研發中最困難的問題之一:如何讓藥物精準抵達人體內的目標細胞。
METiS TechBio此次在香港上市的發行價為每股10.50港元,總計發行約2.01億股,募資約21.1億港元(約2.7億美元)。[10]
上市當天,股票開盤價為28.68港元,比發行價高出約173%,盤中最高漲幅一度達到約185%。[2][
12]
此次IPO採用香港交易所的第18C章上市制度。這是為「專精科技公司」(Specialist Technology Companies)設立的框架,允許尚未盈利、但具有高科技潛力的企業提前上市募資。[9]
Studio Global AI
Use this topic as a starting point for a fresh source-backed answer, then compare citations before you share it.
METiS TechBio在香港IPO募資約21.1億港元(約2.7億美元),發行價10.50港元,首日開盤28.68港元,較發行價暴漲約173%,盤中一度上漲約185%。[2][12]
METiS TechBio在香港IPO募資約21.1億港元(約2.7億美元),發行價10.50港元,首日開盤28.68港元,較發行價暴漲約173%,盤中一度上漲約185%。[2][12] 公司利用人工智慧與奈米材料設計藥物遞送系統,被形容為可將治療分子精準送入細胞的「奈米火箭」。[1][10]
香港市場近年出現AI生技IPO熱潮,已有超過10家尚未盈利的生技公司申請上市,顯示投資人對AI藥物研發平台興趣迅速升溫。[20]
繼續閱讀「中國「影子 API」灰色市場:開發者如何繞過限制使用 Claude、Gemini 與 ChatGPT」,從另一個角度查看更多引用來源。
開啟相關頁面將這個答案與「六人座電動SUV崛起:中國高端EV市場的新戰場」交叉比對。
開啟相關頁面AI Drug Delivery Startup Metis Clears Hong Kong IPO Hurdle ... Founded in 2020, Metis uses artificial intelligence to address complex drug delivery challenges, particularly in the development of lipid nanoparticle systems Chinese AI-driven drug delivery sta...
AI drug-delivery developer Metis shares jump after Hong Kong IPO By Li Jing chinadaily.com.cn Updated: 2026-05-13 13:17 ... Shares of Chinese AI drug-delivery developer Metis TechBio Co Ltd opened at HK$28.68, up 173.14 percent from its IPO price on its tra...
METIS TECHBIO-P Listing Date 2026/05/13 Listed Today -- -- Listing Price 10.500 - Subscription Rate6,910.96x - Guarantee One Lot Size800 lot - One Lot Success Rate0.14% ... Metis TechBio Co. is a pioneer in AI-empowered nanomaterial innovation, dedicated to...
O’Melveny Advises on First IPO of an AI Nano-Delivery Company in US$270 Million Hong Kong Chapter 18C Listing of Metis TechBiohBMay 13, 2026 ... HONG KONG—May 13, 2026— O’Melveny represented joint sponsors and other underwriters in the initial public offeri...
強勢的首日表現,使這次IPO成為當年香港市場規模最大的醫療健康類上市之一,也反映出投資人對AI驅動生技公司的高度期待。[2]
METiS TechBio成立於2020年,核心業務是利用人工智慧來設計與優化藥物遞送系統。[1]
在許多新型療法(例如RNA藥物或基因療法)中,最大的挑戰並不是藥物本身,而是如何把它安全、有效地送到人體特定細胞。METiS的解決方案,是結合AI與奈米材料技術來設計「載體」。
公司建立了一整套AI工具,用於設計、測試與優化這些奈米材料,使研究人員能更快找到有效的遞送方案。[8]
一些媒體把這種技術形容為**「奈米火箭(nano‑rockets)」**——微小的工程化粒子,能把藥物精準送到特定細胞。[10]
這個比喻其實說明了公司的商業模式:
與其只開發單一藥物,METiS希望打造一個可支援多種療法的技術平台。
如果藥物遞送技術能大幅提升治療效果或安全性,它就可能成為整個製藥產業的重要基礎設施,讓不同藥企都能利用這個平台開發新療法。
METiS TechBio的熱度並不是孤例,而是香港市場近年AI生技投資潮的一部分。
幾個因素推動了這股趨勢:
首先,AI藥物研發的突破吸引了大量資本。AI可以加速藥物設計、分子篩選與遞送系統開發,理論上能大幅縮短研發周期。
其次,香港交易所改革上市制度,為尚未盈利的生技與深科技公司提供上市渠道。
再者,全球投資人正積極尋找人工智慧在醫療領域的應用機會。
目前已有超過10家尚未盈利的生技公司申請在香港上市,其中不少都主打AI藥物研發或AI藥物設計平台。[20]
同時,香港IPO市場整體也在回溫。2026年第一季共有40家公司上市、募資1,104億港元,遠高於2025年同期的17宗IPO與187億港元。[18]
儘管上市首日表現亮眼,但早期生技公司仍然伴隨高度不確定性。
包括:
IPO首日的大幅上漲,往往反映的是市場對未來潛力的期待,而不是已經證明的商業成功。
METiS TechBio的上市,反映了一個更大的趨勢:人工智慧正在重塑製藥產業的研發模式。
如果AI設計的藥物遞送平台最終在臨床上取得成功,它可能加速多種療法的開發,包括RNA藥物、基因療法以及下一代生物製劑。
但真正的考驗仍在未來幾年——當這些技術從概念與平台,走向真正被批准上市的藥物時,市場才能判斷它們是否改變了醫藥產業。
中國「影子 API」灰色市場:開發者如何繞過限制使用 Claude、Gemini 與 ChatGPT
Shares of METiS TechBio surged 173 per cent on their Hong Kong debut on Wednesday as the AI-driven drug design start-up's initial public offering drew strong demand from investors amid buoyant sentiment for AI-related stocks in the city. Its stocks first tr...
Metis TechBio shares jump 185% as hot HK debuts extend run By Bloomberg Shares of Metis TechBio Co, a biotechnology company using artificial intelligence to deliver and formulate drugs, surged as much as 185 percent in their Hong Kong debut on Wednesday, ad...
Startup Trung Quốc gây 'sốt sàn chứng khoán' nhờ AI thiết kế thuốc Startup công nghệ sinh học METiS TechBio của Trung Quốc đang gây chú ý khi sử dụng AI để thiết kế các 'nano-rocket' có khả năng đưa thuốc chính xác đến tế bào bệnh. Công ty vừa tăng hơn 170%...
This Q1 2026 round-up summarises key trading and fundraising indicators in what was a robust start to the year across Hong Kong’s primary and secondary markets. ... - Number of IPOs: 40, compared with 17 in Q1 2025 - Total funds raised via IPOs: HK$110.4 bi...
Hong Kong attracts wave of biotech IPO filings amid AI drug research boom More than 10 pre-profit drug developers are seeking Hong Kong listings as AI-powered biotech platforms draw growing investor interest 3-MIN READ3-MIN ... More than 10 loss-making biot...